Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ronnie Aronson
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycemic ThErapy (IMMEDIATE): A Randomized Clinical Trial
Abstract Aims To examine the efficacy and patient satisfaction of intermittently scanned continuous glucose monitoring (isCGM) in adults using non-insulin therapies for management of type 2 diabetes. Materials and Methods The IMMEDIATE study was a multi-site, open label, randomized clinical trial with follow-up at 16 weeks.
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial | Diabetes Care
Emerging Therapies: Drugs and Regimens Abstract OBJECTIVE To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes.
Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial
Original Research Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial Thomas R. Pieber, Ronnie Aronson, Ulrike Hövelmann, Julie Willard, Leona Plum-Mörschel, Kim M.
Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)
Abstract Aims To investigate real‐world short‐term clinical outcomes in adults with type 2 diabetes (T2D) who initiated semaglutide in a specialist endocrinology practice in Canada. Materials and methods This study was a retrospective observational study using data from the Canadian LMC Diabetes Registry.
Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-c
Summary Background People with type 1 diabetes who use continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) often remove their pump before extended periods of exercise, but this approach might result in reduced glycaemic control and increased risk of hyperglycaemia and ketogenesis. We aimed to assess the efficacy and safety of a hybrid approach, in which basal insulin delivery was divided between CSII and a daily injection of insulin degludec.
Optimizing Diabetes Self-management Using the Novel Skills, Confidence, and Preparedness Index (SCPI)
Clinical Care/Education/Nutrition/Psychosocial Research Abstract OBJECTIVE The Skills, Confidence, and Preparedness Index (SCPI) is an electronic tool designed to assess three dimensions (knowledge, confidence, and preparedness) in a clinically relevant measure with immediate feedback to guide the individualization of patient education. This study sought to assess the validity and reliability of the final SCPI generation, its relevance to glycemia, and its responsiveness to patient education.
First Assessment of the Performance of an Implantable CGM System Through 180 Days in a Primarily Adolescent Population with Type I Diabetes
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies
Abstract Aims Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real‐world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non‐interventional real‐world study of hypoglycaemia, assessed hypoglycaemia in 27 585 individuals across 24 countries.
Optimal Insulin Correction Factor in Post-High-Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study
Clinical Care/Education/Nutrition/Psychosocial Research Abstract OBJECTIVE Postexercise hyperglycemia, following high-intensity interval training (HIIT) in patients with type 1 diabetes (T1D), is largely underrecognized by the clinical community and generally undertreated. The aim of this study was to compare four multipliers of an individual’s insulin correction factor (ICF) to treat post-HIIT hyperglycemia.
Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real‐world studies
Aims Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in real‐world clinical practice. Current data on hypoglycaemia are generally limited to those reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT) study, a non‐interventional real‐world study of hypoglycaemia, assessed hypoglycaemia in 27,585 people across 24 countries.
Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
Maintaining optimal glycaemic control reduces the risk of micro‐/macrovascular complications in patients with type 2 diabetes. Typically, glycaemic control is based on HbA1c as a measure of mean glucose concentration. However, this parameter does not accurately reflect glycaemic variability (GV), which is characterized by the amplitude, frequency, and duration of hypo‐/hyperglycaemic fluctuations.
6-month implantable CGM safe, accurate in teens, adults
ORLANDO, Fla. — A continuous glucose monitoring system with a fully implantable sensor and compatible mobile app demonstrated more than 80% agreement with reference glucose values over 180 days of continuous wear in a group of mostly adolescent patients with type 1 diabetes, according to a speaker here. The Eversense XL (Senseonics) CGM is approved in Europe for use in adults for up to 180 days, and Thursday, the FDA approved the Eversense CGM for use in adults for up to 90 days.
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study - Aronson - 2018 - Diabetes, Obesity and Metabolism - Wiley Online Library
This phase III, multicentre, randomized study (ClinicalTrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53‐91 mmol/mol]) despite diet and exercise. The 52‐week study comprised a 26‐week, double‐blind, placebo‐controlled period (Phase A) during which 461 participants received placebo, ertugliflozin 5 mg/d or ertugliflozin 15 mg/d.
Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes
These data from the global HAT study confirm that hypoglycaemia results in an increase in healthcare utilisation, contributing to an increased economic burden of diabetes management on healthcare payers in those countries where costs are not borne solely by patients.
Assessment of self-management in patients with diabetes using the novel LMC Skills, Confidence and Preparedness Index (SCPI)
Publication HistoryPublished online: October 30, 2017Accepted: October 26, 2017; Received in revised form: October 16, 2017; Received: May 17, 2017;
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Di
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial | Diabetes C
AbstractOBJECTIVE To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a second oral glucose-lowering drug.RESEARCH DESIGN AND METHODS After a 4-week run-in to optimize metformin and stop other oral antidiabetic drugs, participants (N = 1,170, mean diabetes...
Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C) | Diabetes Care
Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C) Ronnie Aronson, Naomi Orzech, Chenglin Ye, Ruth E. Brown, Ronald Goldenberg, Vivien Brown Diabetes Care Oct 2016, 39 (10) 1711-1717; DOI: 10.2337/dc15-2666
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ronnie
Contact Ronnie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack